SR One Capital Management, LP - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 12, 2026, for the 2025 Q4 period, SR One Capital Management, LP held in its portfolio 13 assets valued at $706,376,583 (i.e. $706.38M).

The most valuable assets in the portfolio included: Zenas BioPharma, Inc ($182.92M), Arcellx, Inc. ($153.00M), and CRISPR Therapeutics AG ($106.91M).

The chart below shows the top 10 valuable assets, and the table below shows the top 13 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in SR One Capital Management, LP Portfolio

Zenas BioPharma, Inc

Arcellx, Inc.

CRISPR Therapeutics AG

Design Therapeutics, Inc.

Mineralys Therapeutics Inc.

ARS Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc.

Alumis Inc.

Oruka Therapeutics, Inc

Oculis Holding AG

SR One Capital Management, LP - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Zenas BioPharma, Inc	5037854	182924479	Common Stock
Arcellx, Inc.	2346630	153000276	Common Stock
CRISPR Therapeutics AG	2038763	106912732	Common Shares
Design Therapeutics, Inc.	6526476	61218345	Common Stock
Mineralys Therapeutics Inc.	1563966	56756326	Common Stock
ARS Pharmaceuticals, Inc.	4012903	46750320	Common Stock
ORIC Pharmaceuticals, Inc.	4514929	37753841	Common Stock
Alumis Inc.	1959896	19128585	Common Stock
Oruka Therapeutics, Inc	430330	13043302	Common Stock
Oculis Holding AG	641022	12801209	Ordinary Shares
enGene Holdings Inc.	747750	6752183	Common Shares
Nkarta, Inc.	3333333	6166666	Common Stock
Ultragenyx Pharmaceutical Inc.	137753	3168319	Common Stock